What happens when you stop taking a peptide? Do the benefits reverse?

Benefits that depend on continued receptor activation often fade as a drug leaves the body. In SURMOUNT-4, people first received tirzepatide for 36 weeks, then continued it or switched to placebo. Over the following year, the withdrawal group regained an average of 14% of its week-36 body weight, while the continuing group lost another 5.5%. The withdrawal group still averaged below its original starting weight, so “everyone loses every benefit immediately” would also be wrong.[1]

The pattern is not unique to GLP-1 treatment. A tesamorelin trial found that its visceral-fat benefit was rapidly lost after switching to placebo, whereas continued treatment maintained the reduction. This illustrates the difference between treating an ongoing physiological tendency and permanently removing its cause. Return of an underlying condition is not, by itself, evidence of addiction or permanent suppression.[2]

For healing peptides, durable repair is possible in principle if an injury truly heals, but good human evidence has not established whether BPC-157 creates such repair or how lasting any benefit is after stopping. Pain relief alone cannot answer that question. The relevant evidence is follow-up after withdrawal, including function, recurrence, and structural outcomes where appropriate, rather than assuming either that all effects persist or that all disappear.[3]